Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2016 | 2 |
2017 | 2 |
2018 | 1 |
2024 | 0 |
Search Results
4 results
Results by year
Filters applied: . Clear all
Page 1
Practical differences between luteinizing hormone-releasing hormone agonists in prostate cancer: perspectives across the spectrum of care.
Ther Adv Urol. 2017 Nov 23;10(2):51-63. doi: 10.1177/1756287217738985. eCollection 2018 Feb.
Ther Adv Urol. 2017.
PMID: 29434673
Free PMC article.
Review.
METHODS: A review was conducted to summarize the information on the different LHRH agonist formulations currently available and offer insight into their relative benefits and disadvantages from the perspectives of physicians, a pharmacist, and a nurse. RESULTS: The leuprorelin ac …
METHODS: A review was conducted to summarize the information on the different LHRH agonist formulations currently available and offer insigh …
Testosterone suppression with a unique form of leuprorelin acetate as a solid biodegradable implant in patients with advanced prostate cancer: results from four trials and comparison with the traditional leuprorelin acetate microspheres formulation.
Solarić M, Bjartell A, Thyroff-Friesinger U, Meani D.
Solarić M, et al.
Ther Adv Urol. 2017 Apr 18;9(6):127-136. doi: 10.1177/1756287217701665. eCollection 2017 Dec.
Ther Adv Urol. 2017.
PMID: 28588651
Free PMC article.
BACKGROUND: There are two slow-release ready-to-use forms of leuprorelin acetate (1-month and 3-month) that are available as solid, biodegradable implants for the treatment of advanced, hormone-sensitive prostate cancer. ...
BACKGROUND: There are two slow-release ready-to-use forms of leuprorelin acetate (1-month and 3-month) that are available as solid, b …
Item in Clipboard
Ercc1 Deficiency Promotes Tumorigenesis and Increases Cisplatin Sensitivity in a Tp53 Context-Specific Manner.
Jokić M, Vlašić I, Rinneburger M, Klümper N, Spiro J, Vogel W, Offermann A, Kümpers C, Fritz C, Schmitt A, Riabinska A, Wittersheim M, Michels S, Ozretić L, Florin A, Welcker D, Akyuz MD, Nowak M, Erkel M, Wolf J, Büttner R, Schumacher B, Thomale J, Persigehl T, Maintz D, Perner S, Reinhardt HC.
Jokić M, et al.
Mol Cancer Res. 2016 Nov;14(11):1110-1123. doi: 10.1158/1541-7786.MCR-16-0094. Epub 2016 Aug 11.
Mol Cancer Res. 2016.
PMID: 27514406
Furthermore, tumors that relapsed after cisplatin treatment in our model develop a robust etoposide sensitivity that is independent of the Ercc1 status and depends solely on previous cisplatin exposure. Our results provide a solid rationale for further investigation of the …
Furthermore, tumors that relapsed after cisplatin treatment in our model develop a robust etoposide sensitivity that is independent of the E …
Item in Clipboard
Impact of Surgical Approach on Clinical Outcomes in the Treatment of Lumbar Pseudarthrosis.
Owens RK 2nd, Djurasovic M, Crawford CH 3rd, Glassman SD, Dimar JR 2nd, Carreon LY.
Owens RK 2nd, et al.
Global Spine J. 2016 Dec;6(8):786-791. doi: 10.1055/s-0036-1582390. Epub 2016 Apr 6.
Global Spine J. 2016.
PMID: 27853663
Free PMC article.
This result further emphasizes the importance of achieving a solid fusion with the index surgery....
This result further emphasizes the importance of achieving a solid fusion with the index surgery....
Item in Clipboard
Cite
Cite